PMID- 33234149 OWN - NLM STAT- MEDLINE DCOM- 20210607 LR - 20210607 IS - 1475-2840 (Electronic) IS - 1475-2840 (Linking) VI - 19 IP - 1 DP - 2020 Nov 24 TI - Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study. PG - 197 LID - 10.1186/s12933-020-01167-5 [doi] LID - 197 AB - BACKGROUND: The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. METHODS: Circulating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively. RESULTS: The median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e' (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (beta = 0.89, P < 0.01) and worsening of average E/e' (beta = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16-6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease. CONCLUSION: Circulating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD. FAU - Wu, Mei-Zhen AU - Wu MZ AD - Division of Cardiology, Department of Medicine, the University of Hong Kong Shenzhen Hospital, Shen Zhen, China. AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Lee, Chi-Ho AU - Lee CH AD - Division of Endocrinology, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China. FAU - Chen, Yan AU - Chen Y AD - Department of Ultrasound, Shenzhen Hospital, Southern Medical University, Shen Zhen, China. FAU - Yu, Shuk-Yin AU - Yu SY AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Yu, Yu-Juan AU - Yu YJ AD - Division of Cardiology, Department of Medicine, the University of Hong Kong Shenzhen Hospital, Shen Zhen, China. AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Ren, Qing-Wen AU - Ren QW AD - Division of Cardiology, Department of Medicine, the University of Hong Kong Shenzhen Hospital, Shen Zhen, China. AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Fong, Ho-Yi Carol AU - Fong HC AD - Division of Endocrinology, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China. FAU - Wong, Pui-Fai AU - Wong PF AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Tse, Hung-Fat AU - Tse HF AD - Division of Cardiology, Department of Medicine, the University of Hong Kong Shenzhen Hospital, Shen Zhen, China. AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. FAU - Lam, Siu-Ling Karen AU - Lam SK AD - Division of Endocrinology, Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, China. FAU - Yiu, Kai-Hang AU - Yiu KH AD - Division of Cardiology, Department of Medicine, the University of Hong Kong Shenzhen Hospital, Shen Zhen, China. khkyiu@hku.hk. AD - Division of Cardiology, Department of Medicine, the University of Hong Kong, Room 1929C, Block K, Queen Mary Hospital, Hong Kong, China. khkyiu@hku.hk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201124 PL - England TA - Cardiovasc Diabetol JT - Cardiovascular diabetology JID - 101147637 RN - 0 (Biomarkers) RN - 0 (FABP4 protein, human) RN - 0 (Fatty Acid-Binding Proteins) SB - IM MH - Aged MH - Biomarkers/blood MH - Diabetes Mellitus, Type 2/blood/*complications/diagnosis MH - Diastole MH - *Echocardiography, Doppler, Pulsed MH - Fatty Acid-Binding Proteins/*blood MH - Female MH - Humans MH - Hypertrophy, Left Ventricular/diagnostic imaging/*etiology/physiopathology MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prognosis MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Ventricular Dysfunction, Left/diagnostic imaging/*etiology/physiopathology MH - *Ventricular Function, Left MH - *Ventricular Remodeling PMC - PMC7687743 OTO - NOTNLM OT - AFABP OT - Echocardiography OT - Major adverse cardiovascular events OT - Type 2 diabetes COIS- No author has a real or perceived conflict of interest. EDAT- 2020/11/26 06:00 MHDA- 2021/06/08 06:00 PMCR- 2020/11/24 CRDT- 2020/11/25 05:31 PHST- 2020/09/05 00:00 [received] PHST- 2020/10/31 00:00 [accepted] PHST- 2020/11/25 05:31 [entrez] PHST- 2020/11/26 06:00 [pubmed] PHST- 2021/06/08 06:00 [medline] PHST- 2020/11/24 00:00 [pmc-release] AID - 10.1186/s12933-020-01167-5 [pii] AID - 1167 [pii] AID - 10.1186/s12933-020-01167-5 [doi] PST - epublish SO - Cardiovasc Diabetol. 2020 Nov 24;19(1):197. doi: 10.1186/s12933-020-01167-5.